Zhiwei Biopharmaceutical

Zhiwei Biopharmaceutical is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule therapeutics using an integrated artificial intelligence (AI) drug discovery platform. The company leverages its proprietary AI technology to accelerate the identification of high-quality lead compounds and optimize drug candidates for oncology and autoimmune disorders. Its lead programs include next-generation BTK inhibitors and EGFR inhibitors designed to overcome resistance in various cancers. Zhiwei Biopharmaceutical operates research and development facilities in Guangzhou and Suzhou, China, aiming to bridge the gap between computational design and clinical application.